Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia13-06-2018
13-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dear Sirs, Sub: Sun Pharma receives EIR for Halol facility This is with reference to our letter dated June 08, 2018 to the stock exchanges providing our clarification on the US FDA inspection at the Company's Halol facility wherein interalia we had indicated that once we receive the Establishment Inspection Report (EIR), we would immediately inform the exchanges....12-06-2018
Sun Pharma's Halol plant resolution could repair more than its financial health
The resolution of Sun Pharma's Halol plant could add as much as $100 million in revenues annually11-06-2018
Sun Pharma stock gains 8% as company clears FDA's Halol plant hurdle
The Halol plant was reinspected by the FDA in the March quarter, and had received three Form 483 observations09-06-2018
Clarification On News Item
Sub: Clarification /Confirmation on news item appearing in 'Media/Publication' Dear Sirs, We hereby submit our responses as follows with reference to your emails dated today, June 8, 2018 seeking clarification on recent news item in 'www.moneycontrol.com' dated June 08, 2018 captioned 'No re-inspection at Sun Pharma''s Halol unit sends stock soaring 9%'....08-06-2018
Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on June 08, 2018 with reference to news appeared on : www.moneycontrol.com dated June 08, 2018 quoting "No re-inspection at Sun Pharma's Halol unit sends stock soaring 9%".The reply is awaited.08-06-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia07-06-2018
Sun Pharma climbs 2.5%; CLSA upgrades rating to buy'
Sun Pharmaceutical Industries Ltd climbed as much as 2.5 per cent to Rs 485.35, and was among the top percentage gainers on the NSE index.We believ06-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to Sun Pharma receiving prestigious CSR Award, which we shall be releasing after sending this letter to you. This is for your information and record.05-06-2018
Disclosure of Voting results of Court Convened Meeting (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Sun Pharmaceutical Industries Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here02-06-2018